Literature DB >> 29958555

Functionalized Multi-Walled Carbon Nanotubes for Targeting Delivery of Immunostimulatory CpG Oligonucleotides Against Prostate Cancer.

Qingming Xia, Chunai Gong, Fenfen Gu, Zhuo Wang, Chuling Hu, Lijuan Zhang, Lei Qiang, Xueying Ding, Shen Gao, Yuan Gao.   

Abstract

Immuno-based oncotherapy has been successfully implemented for cancer treatment. In the present study, we developed a Oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs (CpG ODNs) nano-delivery system based on Multi-walled carbon nanotubes (MWCNTs) conjugated with H3R6 polypeptide (MHR-CpG) for prostate cancer immunotherapy. The in vitro and in vivo toxicity data revealed that the prepared MHR showed high biocompatibility. Confocal laser scanning microscopy confirmed that MHR-CpG could specifically target the endosomal TLR9. In addition, the use of MHR enhanced the immunogenicity of CpG in both humoral and cellular immune pathways, as evidenced by the increased expression of CD4+ T-cells, CD8+ T-cells, TNF-α, and IL-6. The in vivo anti-cancer efficacy study on RM-1 tumor-bearing mice demonstrated that MHR-CpG could deliver the immunotherapeutics to the tumor site and the tumor-draining lymph node to suppress tumor growth. These results suggested that MHR-CpG was a promising multifunctional nano system for prostate cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29958555     DOI: 10.1166/jbn.2018.2605

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  10 in total

1.  Carbon Nanospheres Exert Antitumor Effects Associated with Downregulation of 4E-BP1 Expression on Prostate Cancer.

Authors:  Weimin Dong; Yong Luo; Guian Zhang; Hui Zhang; Yuxiang Liang; Yangjia Zhuo; Yingke Liang; Fen Zou; Weide Zhong
Journal:  Int J Nanomedicine       Date:  2020-08-05

Review 2.  Advanced biomaterials for cancer immunotherapy.

Authors:  Fan Yang; Kun Shi; Yan-Peng Jia; Ying Hao; Jin-Rong Peng; Zhi-Yong Qian
Journal:  Acta Pharmacol Sin       Date:  2020-03-02       Impact factor: 6.150

Review 3.  The Role of Toll-Like Receptors in Oncotherapy.

Authors:  Caiqi Liu; Ci Han; Jinfeng Liu
Journal:  Oncol Res       Date:  2019-03-25       Impact factor: 5.574

Review 4.  Polymeric Micelles in Cancer Immunotherapy.

Authors:  Zhuoya Wan; Ruohui Zheng; Pearl Moharil; Yuzhe Liu; Jing Chen; Runzi Sun; Xu Song; Qiang Ao
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

Review 5.  Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy.

Authors:  Neelam Thakur; Saloni Thakur; Sharmistha Chatterjee; Joydeep Das; Parames C Sil
Journal:  Front Chem       Date:  2020-12-21       Impact factor: 5.221

Review 6.  Cancer Targeting and Diagnosis: Recent Trends with Carbon Nanotubes.

Authors:  Ragini Singh; Santosh Kumar
Journal:  Nanomaterials (Basel)       Date:  2022-07-02       Impact factor: 5.719

7.  Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer.

Authors:  Fenfen Gu; Chuling Hu; Wei Cao; Chao Li; Qingming Xia; Yuan Gao; Yan Liu; Shen Gao
Journal:  Int J Nanomedicine       Date:  2022-09-20

8.  Nanocarriers for cancer nano-immunotherapy.

Authors:  Isra Rana; Jaeeun Oh; Juwon Baig; Jeong Hyun Moon; Sejin Son; Jutaek Nam
Journal:  Drug Deliv Transl Res       Date:  2022-10-03       Impact factor: 5.671

9.  Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.

Authors:  Wenjun Jiang; Jiyuan Chen; Chunai Gong; Yuanyuan Wang; Yuan Gao; Yongfang Yuan
Journal:  J Nanobiotechnology       Date:  2020-03-18       Impact factor: 10.435

Review 10.  A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers.

Authors:  Safiye Akkın; Gamze Varan; Erem Bilensoy
Journal:  Molecules       Date:  2021-06-03       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.